Chinook Therapeutics to Present at Upcoming Investor Conferences
Retrieved on:
Tuesday, November 22, 2022
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases.
Key Points:
- Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases.
- Chinooks product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways.
- Chinooks lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases.
- In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases.